Integrated Quality by Design (QbD) Approaches to Nasal Spray Characterization: Regulatory Compliance, Analytical Methodologies, and Bioequivalence Evaluation for Suspension and Solution Products
Running title: Nasal Spray Testing and FDA Regulatory Compliance
Keywords:
Nasal Drug Delivery, Bioequivalence, Fluticasone Propionate, FDA Guidance, Spray Pattern, Plume Geometry, Droplet Size Distribution (DSD), CMCAbstract
The administration of therapeutic agents via the nasal route has evolved from simple local decongestants to complex systemic delivery systems. Ensuring the safety and reproducibility of these combination products requires rigorous adherence to regulatory standards, specifically US FDA mandates and USP <601>. This review provides a technical overview of the Critical Quality Attributes (CQAs) necessary for development and approval, focusing on the "weight of evidence" approach for generic bioequivalence (BE). Unlike oral forms, nasal sprays rely on in vitro characterization-including Droplet Size Distribution (DSD), Spray Pattern, Plume Geometry, and Delivered Dose Uniformity (DDU)-to predict in vivo deposition. We discuss the necessity of automated actuation to mitigate operator variability and ensure statistical compliance with Population Bioequivalence (PBE) limits. Special consideration is given to suspension-based formulations where particle size management is critical. By synthesizing current regulatory guidance with practical analytical strategies, this work serves as an essential roadmap for aligning formulation rheology with device mechanics for successful product commercialization.
References
1. Djupesland, P. G. (2013). Nasal drug delivery devices: characteristics and performance in a clinical perspective—a review. Drug delivery and translational research, 3(1), 42-62.
2. Behl, C. R., Pimplaskar, H. K., Sileno, A. P., Demeireles, J., & Romeo, V. D. (1998). Effects of physicochemical properties and other factors on systemic nasal drug delivery. Advanced drug delivery Reviews, 29(1-2), 89-116.
3. FDA: Guidance for Industry: Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products — Chemistry, Manufacturing, and Controls Documentation. Center for Drug Evaluation and Research (CDER) 2002.
4. FDA: Guidance for Industry: Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action. CDER 2003.
5. Adams WP, et al: (2001). Regulatory aspects of modifications to innovator products. Journal of Pharmaceutical Innovation 3: 1-10.
6. GlaxoSmithKline. (2019). Flonase allergy relief (fluticasone propionate) prescribing information.
7. Schuman, T. (2019). Leak testing of nasal spray container closure systems. Packaging Science, 44(2).
8. Proveris Scientific. (2021). Automated actuation vs. manual testing in nasal spray characterization (Technical white paper).
9. Newman, S. P. (2005). Principles of metered-dose inhaler design. Respiratory care, 50(9), 1177-1190.
10. Guo, C., & Doub, W. H. (2006). The influence of actuation parameters on in vitro testing of nasal spray products. Journal of pharmaceutical sciences, 95(9), 2029-2040.
11. Dayal, P., Shaik, M. S., & Singh, M. (2004). Evaluation of different parameters that affect droplet‐size distribution from nasal sprays using the Malvern Spraytec®. Journal of pharmaceutical sciences, 93(7), 1725-1742.
12. Lionberger, R. A. (2008). FDA critical path initiatives: opportunities for generic drug development. The AAPS journal, 10(1), 103-109.
13. Farina, D. J. (2010). Visualization of nasal spray plumes: High-speed imaging techniques. Vision Systems Design, 15(2).
14. Doub, W. H., et al. (2007). Effects of formulation viscosity on the spray characteristics of nasal sprays. Drug Development and Industrial Pharmacy, 33(11), 1200–1207.
15. FDA: Guidance for Industry: Statistical Approaches to Establishing Bioequivalence. CDER 2001.
16. Zijlstra, G. S., et al. (2022). Correlation between in vitro spray characterization and in vivo deposition. International Journal of Pharmaceutics, 612, 121–135.
17. U.S. Food and Drug Administration. (2019). Draft guidance on fluticasone propionate nasal spray. Office of Generic Drugs.
18. D’Souza, S. (2014). A review of in vitro drug release test methods for nano‐sized dosage forms. Advances in pharmaceutics, 2014(1), 304757.
19. Kimbell, J. S., et al. (2018). Nasal deposition of varying spray characteristics: In vitro tests in human nasal casts. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 31(4), 211–220.
20. Suman, J. D. (2003). Nasal drug delivery. Expert opinion on biological therapy, 3(3), 519-523.
21. Eckstein, B. (2015). Delivered dose uniformity of nasal sprays: A practical review. Inhalation Magazine, 9(3), 12–16.
